Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Pharmaceut...

FDA Recall #D-1343-2022 — Class II — July 28, 2022

Recall #D-1343-2022 Date: July 28, 2022 Classification: Class II Status: Terminated

Product Description

Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202 NDC: 68180-658-06

Reason for Recall

CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.

Recalling Firm

Lupin Pharmaceuticals Inc. — Baltimore, MD

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

7,872/30 count bottles

Distribution

Product was distributed nationwide.

Code Information

Lot #A200170, exp. date December 2023

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated